Selected research
Industry Research
Cancer Pain Industry Research Report 2026
Market perspective
The global Cancer Pain market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cancer Pain market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cancer Pain market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cancer Pain market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cancer Pain include Teva pharmaceuticals, Sanofi, Johnson＆Johnson, Eli-Lilly, WEX Pharmaceuticals, ProStrakan Group, Orexo, Meda Pharmaceuticals and GW Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cancer Pain market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cancer Pain.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Pain Market by Company
Teva pharmaceuticals
Sanofi
Johnson＆Johnson
Eli-Lilly
WEX Pharmaceuticals
ProStrakan Group
Orexo
Meda Pharmaceuticals
GW Pharmaceuticals
Grunenthal Group
BioDelivery Science
Cancer Pain Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Cancer Pain Segment by Application
Hormone Therapy
Chemotherapy
Radiotherapy
Others
Cancer Pain Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Pain.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cancer Pain companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Opioids
- Non-Steroidal Anti-Inflammatory Drugs
- Others
Applications
- Hormone Therapy
- Chemotherapy
- Radiotherapy
- Others
Companies covered
- Teva pharmaceuticals
- Sanofi
- Johnson＆Johnson
- Eli-Lilly
- WEX Pharmaceuticals
- ProStrakan Group
- Orexo
- Meda Pharmaceuticals
- GW Pharmaceuticals
- Grunenthal Group
- BioDelivery Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cancer Pain by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Opioids
- 2.2.3 Non-Steroidal Anti-Inflammatory Drugs
- 2.2.4 Others
- 2.3 Cancer Pain by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hormone Therapy
- 2.3.3 Chemotherapy
- 2.3.4 Radiotherapy
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Cancer Pain Breakdown Data by Type
- 3.1 Global Cancer Pain Historic Market Size by Type (2021-2026)
- 3.2 Global Cancer Pain Forecasted Market Size by Type (2027-2032)
4 Cancer Pain Breakdown Data by Application
- 4.1 Global Cancer Pain Historic Market Size by Application (2021-2026)
- 4.2 Global Cancer Pain Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cancer Pain Market Perspective (2021-2032)
- 5.2 Global Cancer Pain Growth Trends by Region
- 5.2.1 Global Cancer Pain Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cancer Pain Historic Market Size by Region (2021-2026)
- 5.2.3 Cancer Pain Forecasted Market Size by Region (2027-2032)
- 5.3 Cancer Pain Market Dynamics
- 5.3.1 Cancer Pain Industry Trends
- 5.3.2 Cancer Pain Market Drivers
- 5.3.3 Cancer Pain Market Challenges
- 5.3.4 Cancer Pain Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cancer Pain Players by Revenue
- 6.1.1 Global Top Cancer Pain Players by Revenue (2021-2026)
- 6.1.2 Global Cancer Pain Revenue Market Share by Players (2021-2026)
- 6.2 Global Cancer Pain Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cancer Pain Head Office and Area Served
- 6.4 Global Cancer Pain Players, Product Type & Application
- 6.5 Global Cancer Pain Manufacturers Established Date
- 6.6 Global Cancer Pain Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cancer Pain Market Size (2021-2032)
- 7.2 North America Cancer Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cancer Pain Market Size by Country (2021-2026)
- 7.4 North America Cancer Pain Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cancer Pain Market Size (2021-2032)
- 8.2 Europe Cancer Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cancer Pain Market Size by Country (2021-2026)
- 8.4 Europe Cancer Pain Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cancer Pain Market Size (2021-2032)
- 9.2 Asia-Pacific Cancer Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cancer Pain Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cancer Pain Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cancer Pain Market Size (2021-2032)
- 10.2 South America Cancer Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cancer Pain Market Size by Country (2021-2026)
- 10.4 South America Cancer Pain Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cancer Pain Market Size (2021-2032)
- 11.2 Middle East & Africa Cancer Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cancer Pain Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cancer Pain Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva pharmaceuticals
- 12.1.1 Teva pharmaceuticals Company Information
- 12.1.2 Teva pharmaceuticals Business Overview
- 12.1.3 Teva pharmaceuticals Revenue in Cancer Pain Business (2021-2026)
- 12.1.4 Teva pharmaceuticals Cancer Pain Product Portfolio
- 12.1.5 Teva pharmaceuticals Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Cancer Pain Business (2021-2026)
- 12.2.4 Sanofi Cancer Pain Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Johnson＆Johnson
- 12.3.1 Johnson＆Johnson Company Information
- 12.3.2 Johnson＆Johnson Business Overview
- 12.3.3 Johnson＆Johnson Revenue in Cancer Pain Business (2021-2026)
- 12.3.4 Johnson＆Johnson Cancer Pain Product Portfolio
- 12.3.5 Johnson＆Johnson Recent Developments
- 12.4 Eli-Lilly
- 12.4.1 Eli-Lilly Company Information
- 12.4.2 Eli-Lilly Business Overview
- 12.4.3 Eli-Lilly Revenue in Cancer Pain Business (2021-2026)
- 12.4.4 Eli-Lilly Cancer Pain Product Portfolio
- 12.4.5 Eli-Lilly Recent Developments
- 12.5 WEX Pharmaceuticals
- 12.5.1 WEX Pharmaceuticals Company Information
- 12.5.2 WEX Pharmaceuticals Business Overview
- 12.5.3 WEX Pharmaceuticals Revenue in Cancer Pain Business (2021-2026)
- 12.5.4 WEX Pharmaceuticals Cancer Pain Product Portfolio
- 12.5.5 WEX Pharmaceuticals Recent Developments
- 12.6 ProStrakan Group
- 12.6.1 ProStrakan Group Company Information
- 12.6.2 ProStrakan Group Business Overview
- 12.6.3 ProStrakan Group Revenue in Cancer Pain Business (2021-2026)
- 12.6.4 ProStrakan Group Cancer Pain Product Portfolio
- 12.6.5 ProStrakan Group Recent Developments
- 12.7 Orexo
- 12.7.1 Orexo Company Information
- 12.7.2 Orexo Business Overview
- 12.7.3 Orexo Revenue in Cancer Pain Business (2021-2026)
- 12.7.4 Orexo Cancer Pain Product Portfolio
- 12.7.5 Orexo Recent Developments
- 12.8 Meda Pharmaceuticals
- 12.8.1 Meda Pharmaceuticals Company Information
- 12.8.2 Meda Pharmaceuticals Business Overview
- 12.8.3 Meda Pharmaceuticals Revenue in Cancer Pain Business (2021-2026)
- 12.8.4 Meda Pharmaceuticals Cancer Pain Product Portfolio
- 12.8.5 Meda Pharmaceuticals Recent Developments
- 12.9 GW Pharmaceuticals
- 12.9.1 GW Pharmaceuticals Company Information
- 12.9.2 GW Pharmaceuticals Business Overview
- 12.9.3 GW Pharmaceuticals Revenue in Cancer Pain Business (2021-2026)
- 12.9.4 GW Pharmaceuticals Cancer Pain Product Portfolio
- 12.9.5 GW Pharmaceuticals Recent Developments
- 12.10 Grunenthal Group
- 12.10.1 Grunenthal Group Company Information
- 12.10.2 Grunenthal Group Business Overview
- 12.10.3 Grunenthal Group Revenue in Cancer Pain Business (2021-2026)
- 12.10.4 Grunenthal Group Cancer Pain Product Portfolio
- 12.10.5 Grunenthal Group Recent Developments
- 12.11 BioDelivery Science
- 12.11.1 BioDelivery Science Company Information
- 12.11.2 BioDelivery Science Business Overview
- 12.11.3 BioDelivery Science Revenue in Cancer Pain Business (2021-2026)
- 12.11.4 BioDelivery Science Cancer Pain Product Portfolio
- 12.11.5 BioDelivery Science Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst